Overview

Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

A Phase III, multi-center, randomized, controlled study designed to demonstrate the efficacy and safety of Cyclosporine Inhalation Solution (CIS)in improving survival and preventing bronchiolitis obliterans syndrome (BOS) when given prophylactically to lung transplant recipients in addition to their standard immunosuppressive regimen.

Phase:

Phase 3

Details

Lead Sponsor:

APT Pharmaceuticals, Inc.

Treatments:

Cyclosporine
Cyclosporins
Pharmaceutical Solutions